Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
9 Tips for Avoiding Tax Season Cyber Scams 
Samsung Biologics and AstraZeneca are reportedly dissolving their biosimilar joint venture. They have formed the Archigen Biotech for the JV, and now this is being shut down.
An official of Samsung Biologics, the biotech unit of the Samsung Group, said on Tuesday, May 24, that it has decided to end its joint venture with the British-Swedish multinational pharmaceutical and biotechnology company due to the suspension of the development of a biosimilar product.
According to Yonhap News Agency, the decision came two months after the Samsung Biologics’ board agreed with the liquidation of Archigen Biotech Ltd. The said company was set up in 2014 via a 50-50 joint venture with AstraZeneca.
When it was first established, Archigen Biotech was working on the development of SAIT101, a biosimilar of Rituximab, a monoclonal antibody medication used for the treatment of lymphoma. It was explained that a biosimilar is a similar duplication of an already existing and approved biologic drug.
However, both Samsung Biologics and AstraZeneca halted the biosimilar program and scrapped the Rituxan copy project. It was revealed to have been actually discontinued in the second half of 2020 after competitors such as Celltrion Inc. started marketing the same products.
Fierce Pharma further reported that Archigen Biotech already launched a phase 3 trial of the SAIT101 in June 2016, but the works have been progressing very slowly. In fact, the original target date for the completion of the project has already been pushed back by more than a year.
The results of the trial were revealed last month and showed that the Rituxan biosimilar medication generated a response in 66.3% of patients, which is on par with the 70.6% posted by the originator.
But then, another issue has cropped up - the market for this product is already crowded with other biotech firms introducing their own biosimilars, with some already being sold. Aside from Celltrion, Achigen Biotech is also competing with Teva Pharmaceuticals, Pfizer, Mylan, and Novartis’ Sandoz. With all of these firms, it became apparent to Samsung Biologics and AstraZeneca that the best move now is to scrap their own Rituxan biosimilar product.
